OncoMatch/Clinical Trials/NCT07217600
Ondansetron Orodispersible Film for Vomiting Prevention in Pediatric Radiotherapy
Is NCT07217600 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Ondansetron orodispersible film once and Ondansetron orodispersible film twice for radiotherapy-induced nausea and vomiting (rinv).
Treatment: Ondansetron orodispersible film once · Ondansetron orodispersible film twice — The goal of this study is to evaluate the antiemetic efficacy and drug safety of ondansetron orodispersible film in pediatric patients with malignant tumors who received moderate emetic risk radiation induced vomiting, and to formulate reasonable and effective clinical medication regimen for preventing vomiting caused by moderate emetic risk radiation in children with malignant tumor.
Check if I qualifyExtracted eligibility criteria
Lab requirements
Blood counts
ANC >= 1.0 × 10^9/L (after discontinuation of G-CSF), PLT >= 50 × 10^9/L (without drug support or transfusion therapy), HGB >= 80g/L
Kidney function
BUN and CRE <= 1.5x ULN
Liver function
total bilirubin <= 1.5x ULN, ALT <= 2.5x ULN, AST <= 2.5x ULN, alkaline phosphatase ≤ 1.5x ULN, serum albumin >= 2.5 g/dL
The blood routine test must meet the following criteria: ANC >= 1.0 × 10^9/L (after discontinuation of G-CSF), PLT >= 50 × 10^9/L (without drug support or transfusion therapy), HGB >= 80g/L; Biochemical tests must meet the following standards: total bilirubin <= 1.5 times ULN (upper limit of normal), ALT <= 2.5 times ULN, AST <= 2.5 times ULN, alkaline phosphatase ≤ 1.5 times ULN, serum albumin >= 2.5 g/dL, BUN and CRE <= 1.5 × ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify